Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935811 | 0.87 | PAOX (0.31) | LMNAPAOXCYP2D6CYP3A4CYP2C19 | |
| SCHEMBL30998792 | 0.79 | TDP1 (0.46) | TDP1LMNAPAOXCYP2D6CYP3A4 | |
| SCHEMBL9957368 | 0.77 | KDM4E (0.34) | PAOXALDH1A1 | |
| SCHEMBL31687256 | 0.73 | TDP1 (0.43) | TDP1LMNAPAOXCYP2D6CYP3A4 | |
| SCHEMBL125043 | 0.71 | SMN1; SMN2 (0.48) | TDP1LMNACYP2D6HPGDDUSP3 | |
| SCHEMBL3712866 | 0.70 | HTR4 (0.34) | TDP1LMNACYP2D6CYP2C19HPGD | |
| SCHEMBL13055322 | 0.69 | GLA (0.52) | LMNAPAOXCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL9936058 | 0.69 | KDM4E (0.38) | ALDH1A1 | |
| SCHEMBL16846559 | 0.69 | SMN1; SMN2 (0.39) | LMNACYP2D6HPGDDUSP3ALDH1A1 | |
| SCHEMBL2616713 | 0.69 | TDP1 (0.55) | TDP1LMNACYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877955-B2 | Secondary aminosilanes | SIKA TECHNOLOGY AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20130281562-A1 | SECONDARY AMINOSILANES | SIKA TECHNOLOGY AG (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2651956-A1 | SECONDARY AMINOSILANES | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2468759-A1 | Secondary Aminosilanes | Sika Technology AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012080266-A1 | SECONDARY AMINOSILANES | SIKA TECHNOLOGY AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281562-A1 | SECONDARY AMINOSILANES | AS3MT, SRM, MSN | TDP1 2124/4885LMNA 3044/4885PAOX 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.